𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design

✍ Scribed by Andrew J. Stewart Coats; Venkatesan Srinivasan; Jayaraman Surendran; Haritha Chiramana; Shankar R. K. G. Vangipuram; Nirajkumar N. Bhatt; Minish Jain; Sandip Shah; Irfhan A. B. H. Ali; Ho G. Fuang; Mohammed Z. M. Hassan; John Beadle; Julia Tilson; Bridget-Anne Kirwan; Stefan D. Anker; on behalf of the ACT-ONE Trial Investigators


Book ID
107703879
Publisher
Springer-Verlag
Year
2011
Tongue
English
Weight
177 KB
Volume
2
Category
Article
ISSN
2190-5991

No coin nor oath required. For personal study only.